Current and emerging antiviral treatments for hepatitis C infection
AuthorDoyle, JS; Aspinall, E; Liew, D; Thompson, AJ; Hellard, ME
Source TitleBRITISH JOURNAL OF CLINICAL PHARMACOLOGY
AffiliationMedicine - Royal Melbourne Hospital
Document TypeJournal Article
CitationsDoyle, J. S., Aspinall, E., Liew, D., Thompson, A. J. & Hellard, M. E. (2013). Current and emerging antiviral treatments for hepatitis C infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 75 (4), pp.931-943. https://doi.org/10.1111/j.1365-2125.2012.04419.x.
Access StatusAccess this item via the Open Access location
Open Access at PMChttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612710
C1 - Journal Articles Refereed
Newly licensed direct acting antivirals for hepatitis C virus HCV are able to cure up to 75% of patients chronically infected with genotype-1 infection, which is the predominant HCV strain in Europe and North America. Emerging antiviral therapies promise further increases in virological response, as well as improved tolerability, reduced duration of therapy, and will potentially eliminate the need for interferon use. This review highlights the main therapeutic agents used in current standard of care, including telaprevir and boceprevir. It goes on to evaluate the mechanisms of emerging drugs, their stage of development and response rates seen in research to date. Finally, it projects into the not too distant future to consider treatment strategies involving combinations of agents and interferon-free therapies, and in which patients they might prove most successful.
KeywordsInfectious Diseases; Clinical Pharmacology and Therapeutics; Preventive Medicine
- Click on "Export Reference in RIS Format" and choose "open with... Endnote".
- Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References